Cardiac mortality assessment improved by evaluation of cardiac sympathetic nerve activity in combination with hemoglobin and kidney function in chronic heart failure patients

Journal of Nuclear Medicine

Volumn 53, Issue 5, 2012, Pages 731-740

  Doi, Takahiro ^a   Nakata, Tomoaki ^a   Hashimoto, Akiyoshi ^a   Yuda, Satoshi ^a   Wakabayashi, Takeru ^a   Kouzu, Hidemichi ^a   Kaneko, Naofumi ^a   Hase, Mamoru ^a   Tsuchihashi, Kazufumi ^a   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anemia; Heart failure; MIBG

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; HEMOGLOBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR PARAMETERS; CLINICAL EVALUATION; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART DEATH; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TO MEDIASTINUM RATIO; HEMOGLOBIN DETERMINATION; HOSPITAL DISCHARGE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SYMPATHETIC FUNCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART FAILURE; HEMOGLOBINS; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SYMPATHETIC NERVOUS SYSTEM; YOUNG ADULT;

EID: 84860708884     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.095786     Document Type: Article

References (39)

1. Tang YD, Katz SD. Anemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113:2454-2461. (Pubitemid 43948053)
2. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients: A systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818-827.
3. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984; 311:819-823. (Pubitemid 14035089)
4. Wieland DM, Wu JI, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: Adrenomedullary imaging with 131I-metaiodobenzylguanidine. J Nucl Med. 1980;21:349-353. (Pubitemid 10100562)
5. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93:1667-1676. (Pubitemid 26131343)
6. Merlet P, Valette H, Dubois-Randle JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-477.
7. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervations assessed by metaiodobenzylguanidine in patients with failing and non-failing heart. J Nucl Cardiol. 1998;5:579-590. (Pubitemid 29015414)
8. Wakabayashi T, Nakata T, Hashimoto A, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med. 2001;42:1757-1767. (Pubitemid 34016342)
9. Nakata T, Wakabayashi T, Nagahara D. Assessment of cardiac innervation in heart failure and lethal arrhythmias: Therapeutic and prognostic implications. Curr Cardiol Rev. 2005;1:29-36.
10. Nishisato K, Hashimoto A, Nakata T, et al. Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: Quantification of cardiac tracers in patients with ICDs. J Nucl Med. 2010;51:1241-1249.
11. Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in chronic heart failure.: Results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart failure) study. J Am Coll Cardiol. 2010;55:2212-2221.
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimated glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461-470. (Pubitemid 29135798)
13. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol. 2009;20:2305-2313.
14. Kyuma M, Nakata T, Hashimoto A, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med. 2004;45:155-163. (Pubitemid 47628373)
15. Clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis. 2001;37(suppl):S182-S238.
16. Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC. Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J. 1993;70:357-362. (Pubitemid 23309546)
17. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35: 681-689. (Pubitemid 30167025)
18. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol. 2002;13:1928-1936. (Pubitemid 34700619)
19. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955-962. (Pubitemid 32912694)
20. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352:1011-1023.
21. Ronco C, McCullogh P, Anker SD, et al. Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31:703-711.
22. Ungerer M, Bohm M, Elce JS, et al. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation. 1993;87:454-463. (Pubitemid 23040915)
23. Miyazaki T, Zipes DP. Presynaptic modulation of efferent sympathetic and vagal neurotransmission in the canine heart by hypoxia, high K1, low pH, and adenosine: Possible relevance to ischemia-induced denervation. Circ Res. 1990;66: 289-301. (Pubitemid 20041161)
24. McGhie AI, Corbett JR, Akers MS, et al. Regional cardiac adrenergic function using I-123 metaiodobenzylguanidine tomographic imaging after myocardial infarction. Am J Cardiol. 1991;67:236-242.
25. Rupérez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation. 2003;108:1499-1505. (Pubitemid 37176458)
26. Galinier M, Pathak A, Fourcade J, et al. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J. 2000;21:475-482. (Pubitemid 30122135)
27. La Rovere MT, Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation. 2003;107:565-570. (Pubitemid 36176805)
28. Arora R, Ferrick KJ, Nakata T, et al. 123I-metaiodobenzylguanidine (MIBG) imaging and heart rate variability analysis to predict the need for implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121-131. (Pubitemid 36503797)
29. Inoue H, Zipes DP. Result of sympathetic denervation in the canine heart: Supersensitivity that may be arrhythmogenic. Circulation. 1987;75:877-887. (Pubitemid 17052673)
30. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: Risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925-1932.
31. Gaddam KK, Ventura HO, Lavie CJ. Metabolic syndrome and heart failure: The risk, paradox, and treatment. Curr Hypertens Rep. 2011;13:142-148.
32. Strandberg TE. Lipid-lowering drugs and heart failure: Where do we go after the statin trials? Curr Opin Cardiol. 2010;25:385-393.
33. Velavan P, Huan Loh P, Clark A, Cleland JG. The cholesterol paradox in heart failure. Congest Heart Fail. 2007;13:336-341.
34. Zhang L, Zhang S, Jiang H, et al. Effects of statin treatment on cardiac function in patients with chronic heart failure: A meta-analysis of randomized controlled trials. Clin Cardiol. 2011;34:117-123.
35. Lyons KS, McVeigh GE, Harbinson MT. Statins in heart failure: Where do we stand? Cardiovasc Drugs Ther. 2011;25:99-104.
36. Nakajima K, Matsubara K, Ishikawa T, et al. Correction of iodine-123-labeled meta-iodobenzylguanidine uptake with multi-window methods for standardization of the heart-to-mediastinum ratio. J Nucl Cardiol. 2007;14: 843-851. (Pubitemid 350082578)
37. Verberne HJ, Habraken JBA, van Eck-Smit BLF, Agostini D, Jacobson AF. Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: A need for standardization and validation. Eur J Nucl Med Mol Imaging. 2008;35:547-553. (Pubitemid 351661673)
38. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BLF. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: A systemic review. Eur Heart J. 2008;29:1147-1159. (Pubitemid 351844881)
39. Kuwabara Y, Tamaki N, Nakata T, Yamashina S, Yamazaki J. Determination of the survival rate in patients with congestive heart failure stratified by 123I-MIBG imaging: A meta-analysis from the studies performed in Japan. Ann Nucl Med. 2011;25:101-107.